TY - JOUR
T1 - Accuracy of diabetes screening methods used for people with tuberculosis, Indonesia, Peru, Romania, South Africa
AU - TANDEM consortium
AU - Grint, Daniel
AU - Alisjhabana, Bachti
AU - Ugarte-Gil, Cesar
AU - Riza, Anca Leila
AU - Walzl, Gerhard
AU - Pearson, Fiona
AU - Ruslami, Rovina
AU - Moore, David A.J.
AU - Ioana, Mihai
AU - McAllister, Susan
AU - Ronacher, Katharina
AU - Koeseomadinata, Raspati C.
AU - Kerry-Barnard, Sarah R.
AU - Coronel, Jorge
AU - Malherbe, Stephanus T.
AU - Dockrell, Hazel M.
AU - Hill, Philip C.
AU - Van Crevel, Reinout
AU - Critchley, Julia A.
N1 - Publisher Copyright:
© 2018, World Health Organization. All rights reserved.
PY - 2018/11
Y1 - 2018/11
N2 - Objective To evaluate the performance of diagnostic tools for diabetes mellitus, including laboratory methods and clinical risk scores, in newly-diagnosed pulmonary tuberculosis patients from four middle-income countries. Methods In a multicentre, prospective study, we recruited 2185 patients with pulmonary tuberculosis from sites in Indonesia, Peru, Romania and South Africa from January 2014 to September 2016. Using laboratory-measured glycated haemoglobin (HbA1c) as the gold standard, we measured the diagnostic accuracy of random plasma glucose, point-of-care HbA1c, fasting blood glucose, urine dipstick, published and newly derived diabetes mellitus risk scores and anthropometric measurements. We also analysed combinations of tests, including a two-step test using point-of-care HbA1cwhen initial random plasma glucose was ≥ 6.1 mmol/L. Findings The overall crude prevalence of diabetes mellitus among newly diagnosed tuberculosis patients was 283/2185 (13.0%; 95% confidence interval, CI: 11.6–14.4). The marker with the best diagnostic accuracy was point-of-care HbA1c (area under receiver operating characteristic curve: 0.81; 95% CI: 0.75–0.86). A risk score derived using age, point-of-care HbA1c and random plasma glucose had the best overall diagnostic accuracy (area under curve: 0.85; 95% CI: 0.81–0.90). There was substantial heterogeneity between sites for all markers, but the two-step combination test performed well in Indonesia and Peru. Conclusion Random plasma glucose followed by point-of-care HbA1c testing can accurately diagnose diabetes in tuberculosis patients, particularly those with substantial hyperglycaemia, while reducing the need for more expensive point-of-care HbA1c testing. Risk scores with or without biochemical data may be useful but require validation.
AB - Objective To evaluate the performance of diagnostic tools for diabetes mellitus, including laboratory methods and clinical risk scores, in newly-diagnosed pulmonary tuberculosis patients from four middle-income countries. Methods In a multicentre, prospective study, we recruited 2185 patients with pulmonary tuberculosis from sites in Indonesia, Peru, Romania and South Africa from January 2014 to September 2016. Using laboratory-measured glycated haemoglobin (HbA1c) as the gold standard, we measured the diagnostic accuracy of random plasma glucose, point-of-care HbA1c, fasting blood glucose, urine dipstick, published and newly derived diabetes mellitus risk scores and anthropometric measurements. We also analysed combinations of tests, including a two-step test using point-of-care HbA1cwhen initial random plasma glucose was ≥ 6.1 mmol/L. Findings The overall crude prevalence of diabetes mellitus among newly diagnosed tuberculosis patients was 283/2185 (13.0%; 95% confidence interval, CI: 11.6–14.4). The marker with the best diagnostic accuracy was point-of-care HbA1c (area under receiver operating characteristic curve: 0.81; 95% CI: 0.75–0.86). A risk score derived using age, point-of-care HbA1c and random plasma glucose had the best overall diagnostic accuracy (area under curve: 0.85; 95% CI: 0.81–0.90). There was substantial heterogeneity between sites for all markers, but the two-step combination test performed well in Indonesia and Peru. Conclusion Random plasma glucose followed by point-of-care HbA1c testing can accurately diagnose diabetes in tuberculosis patients, particularly those with substantial hyperglycaemia, while reducing the need for more expensive point-of-care HbA1c testing. Risk scores with or without biochemical data may be useful but require validation.
UR - http://www.scopus.com/inward/record.url?scp=85056107509&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056107509&partnerID=8YFLogxK
U2 - 10.2471/BLT.17.206227
DO - 10.2471/BLT.17.206227
M3 - Article
C2 - 30455529
AN - SCOPUS:85056107509
SN - 0042-9686
VL - 96
SP - 738
EP - 749
JO - Bulletin of the World Health Organization
JF - Bulletin of the World Health Organization
IS - 11
ER -